Aon's M&A and Transaction Solutions team in France is delighted to have acted as the transaction insurance adviser to Mars on their acquisition of French veterinary diagnostics businesses Cerba Vet and ANTAGENE from CERBA HEALTHCARE. Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland, which provides full animal-related service diagnostics with complete clinical and anatomic pathology testing as well as endocrinology, microbiology, serology, hematology, chemistry, and other advanced tests, to veterinary practitioners. ANTAGENE is a leading player in animal genetics in Europe, recognised for its expertise in DNA testing for dogs, cats, horses and wildlife. ANTAGENE offers tests globally for diagnosing diseases in pets, as well as supporting scientific initiatives to preserve biodiversity. Cerba Vet and ANTAGENE complement Antech, the veterinary diagnostics business of Mars Science & Diagnostics, which provides a full portfolio of diagnostics solutions to veterinary professionals around the world. More about the transaction:https://aon.io/3zryWEr Learn more about Aon's M&A capabilities: https://aon.io/48CebBN
Aon’s Post
More Relevant Posts
-
The Veterinary Diagnostic Laboratory has seen an influx of Anaplasma test requests. Anaplasma marginale, one of the causes of anaplasmosis, is the most common tickborne disease of cattle worldwide. Animals become infected with this organism from ticks and other biting insects, particularly Dermacentor andersoni and other related species. Interestingly, cattle younger 1 year of age generally are asymptomatic or experience very mild illness. Animals older than 2 years routinely display signs of acute and severe anemia as a result of circulating bacteria lysing red blood cells. Pale tissues, low hematocrit and fever are also common findings. The Veterinary Diagnostic laboratory performs PCR for the detection of Anaplasma marginale DNA from EDTA whole blood or from spleen samples. https://buff.ly/3Zug9kA
To view or add a comment, sign in
-
-
Monoclonal antibody (mAb) therapy has been used widely in human health for quite some time but it is relatively new in animal health. In 2016, the introduction of Cytopoint (lokivetmab), used to control atopic dermatitis in dogs, paved the way for mAb therapy in veterinary medicine. Since then, Solensia (frunevetmab) and Librela (bedinvetmab), which both target nerve growth factor (NGF), have been approved for osteoarthritis (OA) pain in cats and dogs, respectively. While Librela (bedinvetmab) is new to the USA market, it has been in use in the European Union for over two years with positive results. The pivotal study conducted in the USA evaluating Librela, resulting in approval by the FDA, has been published in the September 2023 issue of Veterinary Anesthesia and Analgesia. Not surprisingly, the data reported further corroborate the safety and efficacy of bedinvetmab administered monthly to dogs for the control of pain associated with osteoarthritis. What a great innovation! It will be interesting to see how PV monitoring conducted post-marketing will inform even further on it’s safety and efficacy. These are exciting times for advancing the care of our veterinary patients! Let’s Go!! 🚀 #animalhealth #veterinaryindustry #veterinarymedicine #Zoetis
To view or add a comment, sign in
-
📃Scientific paper: Assessment of the diagnostic activity in the parasitology laboratory from the Veterinary College of Alfort (2018-2022) Abstract: International audience; Background and aimsThe main goal of the laboratory of Parasitology at the Veterinary College of Alfort (EnvA) is to offer its expertise in parasite research and identification for the diagnosis of animal parasitic infections. Its activity includes diagnostic services offered to EnvA hospitals, veterinary practitioners and pet breeders. It also provides important teaching support at EnvA. In order to assess its diagnostic activity, we decided to compile and analyse the data collected by the laboratory between 2018 and 2022. Methods All the analytical data produced in our laboratory is stored within a database management software (4D). We extracted all relevant information regarding type of sample, technique requested, host (species, breed and age), and results. All datasets were curated and analysed by descriptive statistics.ResultsIn total, nearly 2500 parasitological analyses were carried out in five years. Most of samples arrived from Paris region. Diagnostic requests comprised 1646 analyses for the detection of helminth eggs and protozoa (direct examination, flotation and formalin-ether sedimentation techniques) and 549 analyses for the detection of nematode larvae (Baermann method). We also treated a smaller number of analyses for parasite detection in blood (serology and Knott test, n=201). We observed a decrease of diagnostic requests during COVID pandemics, but it recovered quickly the next year. The interaction betwee... Continued on ES/IODE ➡️ https://etcse.fr/UMg3V ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.
To view or add a comment, sign in
-
Exciting News! 📢 Our recent publication in the Journal of Veterinary Diagnostic Investigation delves into the realm of AMR in pet rabbits in Hong Kong. 🐇🔬 👏 Read more about our findings and the significant implications for veterinary medicine. #Research #AntimicrobialResistance #VeterinaryScience #PhDResearch #RabbitHealth 🌐📚 Fraser Hill https://lnkd.in/ebN3YD4m
Retrospective analysis of antimicrobial resistance in bacterial pathogens from pet rabbits in Hong Kong, 2019-2022 | Request PDF
researchgate.net
To view or add a comment, sign in
-
Nearly everyone in antibody field may likely know Merck’s PD-1 antibody (Keytruda, the best selling drug in the world) for human use. However, we believe that not many professionals know Merck’s another PD-1 antibody for pets. Merck Animal Health (a division of Merck) announced about two weeks ago its caninized monoclonal antibody gilvetmab (gil-VET-mab) is now available to board certified veterinary oncologists across the United States. Gilvetmab previously received conditional license approval for the treatment of dogs with mast cell tumors and for treatment of dogs with melanoma by the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics (CVB). Belated congratulations to Merck Animal Health! #antibodies #antibody #antibodydiscovery #antibodytherapeutics #mabs #mab #veterinarymabs #veterinaryantibodies #veterinarymedicine #veterinarian #veterinary #veterinarians
Merck Animal Health Announces Availability of Novel Canine Oncology Therapy to Board Certified Veterinary Oncologists Nationwide - Merck Animal Health
merck-animal-health.com
To view or add a comment, sign in
-
#Veterinary #Infectious #Disease #Diagnostics #Market Size and Projections The Veterinary Infectious Disease Diagnostics Market Size was valued at USD 1.76 Billion in 2023 and is expected to reach USD 3.37 Billion by 2031, growing at a 8.9% CAGR from 2024 to 2031. The report comprises of various segments as well an analysis of the trends and factors that are playing a substantial role in the market. The market for veterinary infectious disease diagnostics is expanding significantly due to a rise in pet ownership and growing consciousness of animal health. Diagnostic technology advancements like PCR and immunoassays are improving illness detection speed and accuracy. Furthermore, there is a growing investment in veterinary diagnostics due to the increasing prevalence of zoonotic illnesses. The market is growing as a result of the opening of more veterinary clinics and hospitals as well as more financing going into animal healthcare research. Because of this, the market is expected to grow significantly, with emerging nations exhibiting a discernible rise in demand for cutting-edge veterinary diagnostic services. key Players IDEXX LABORATORIES LIMITED Zoetis. Thermo Fisher Scientific bioMérieux Food Safety & Quality Neogen Corporation
To view or add a comment, sign in
-
-
Check out our latest blog post, which is a quick interview with Christie, our External Innovation & Clinical Trials Manager! She helps explain about the clinical trials process for the veterinary field and what separates it from the human side. Give it a read here: https://hubs.li/Q02jdktz0
Employee Spotlight: Get to Know Christie McCoy — Torigen Pharmaceuticals
torigen.com
To view or add a comment, sign in
-
The One Health dissemination of antimicrobial resistance occurs in both natural and clinical environments https://lnkd.in/dTpD5Mux
Exciting News! 📢 Our recent publication in the Journal of Veterinary Diagnostic Investigation delves into the realm of AMR in pet rabbits in Hong Kong. 🐇🔬 👏 Read more about our findings and the significant implications for veterinary medicine. #Research #AntimicrobialResistance #VeterinaryScience #PhDResearch #RabbitHealth 🌐📚 Fraser Hill https://lnkd.in/ebN3YD4m
Retrospective analysis of antimicrobial resistance in bacterial pathogens from pet rabbits in Hong Kong, 2019-2022 | Request PDF
researchgate.net
To view or add a comment, sign in
-
Explore the world of veterinary #clinicaltrials with us, decoding how specialized dictionaries ensure safety and efficacy in understanding animal Adverse Events (AEs). Our latest blog unravels the intricacies of handling AEs in the unique context of veterinary research. 🐾 Dive into the world of specialized terminology in animal healthcare research. https://hubs.li/Q02x5fJN0 #CTMS #eTMF #EDC #RTSM #Safety #PV #Pharmaceutical #Biotechnology #MedicalDevices #Diagnostics #Cloudbyz #VeterinaryResearch #ClinicalTrials #AnimalSafety #Salesforce Salesforce
Decoding Animal AEs: How Veterinary Clinical Trials Use Specialized Dictionaries to Ensure Safety and Efficacy
https://www.cloudbyz.com/resources
To view or add a comment, sign in
-
Life Sciences | Healthcare | Pharmaceuticals | Therapeutics | Medical Devices & Supplies | Sr. Market Investment Manager
Rise in the prevalence of zoonotic diseases in animals, surge in technological advancements in point-of-care diagnostics, and increase in disposable income levels in the developing regions drive the growth of the global companion animal diagnostics market. On the other hand, lack of skilled veterinary professionals impedes the growth to some extent. However, surge in awareness associated with animal healthcare and increase in adoption of rapid tests and portable instruments in point-of-care diagnostics are projected to create lucrative opportunities in the industry. Download Sample Report - https://lnkd.in/dUPwmmCT The global companion animal diagnostics industry was estimated at $2.99 billion in 2021, and is anticipated to hit $6.88 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031. Key players in the industry- Thermo Fisher Scientific, Inc Zoetis, Inc Agrolabo spa Biomerieux SA Virbac Indical Bioscience Gmbh Fujifilm Holdings Corporation Triviumvet Read More: https://lnkd.in/eTgD9dwA
Companion Animal Diagnostics Market to Reach USD 6.88 Billion, Globally, by 2031 at 8.6% CAGR: Allied Market Research
prnewswire.com
To view or add a comment, sign in
More from this author
-
Aon wspiera program ubezpieczeniowy dla gospodarczej odbudowy Ukrainy/Aon оголосила про запуск програми страхування для відновлення економіки України
Aon 2w -
Aon Insights Series UK 2024
Aon 2mo -
Ubezpieczenia a wykorzystanie cyfryzacji i sztucznej inteligencji oraz energii słonecznej w rozwoju inteligentnych miast
Aon 4mo